Currently out of the existing stock ratings of Jason Zemansky, 17 are a BUY (51.52%), 15 are a HOLD (45.45%), 1 are a SELL (3.03%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 36.42% that have a potential upside of 14.67% achieved within 60 days.

Jason Zemansky’s has documented 64 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CYTK, Cytokinetics at 01-Oct-2025.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on ALVR (ALLOVIR ).
The best stock recommendation documented was for RCUS (ARCUS BIOSCIENCES) at 11/18/2022. The price target of $33 was fulfilled within 12 days with a profit of $5.69 (20.83%) receiving and performance score of 17.36.

Average potential price target upside

of $24.3 (37.77%) on ALVR (ALLOVIR ).
of $13.47 (57.5%) on INSM (INSMED).
of $7.51 (17.87%) on CYTK (CYTOKINETICS).

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences ALVR Allovir KURA Kura Oncology SNDX Syndax Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Wolleben (JMP)